CRVS

Corvus Pharmaceuticals, Inc. (CRVS) - Q2 2026 Filing Summary

Business Context and Reporting Period

This summary covers the unaudited quarterly report on Form 10-Q for Corvus Pharmaceuticals, Inc. for the period ended June 30, 2026. Corvus is a clinical-stage biopharmaceutical company focused on developing product candidates that target immune cell maturation and function. The company's lead asset is soquelitinib (an ITK inhibitor), currently in a potentially registrational Phase 3 trial for relapsed peripheral T-cell lymphomas (PTCL) and a Phase 2 trial for atopic dermatitis. Other candidates include ciforadenant (A2A receptor antagonist) and mupadolimab (anti-CD73 antibody).

Key Financial Metrics

Note: All figures in millions unless otherwise noted. YTD 2025 net income included a $27.1 million non-cash gain from the change in fair value of warrant liability, which did not recur in 2026.

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss for the six months ended June 30, 2026, was $31.7 million, compared to net income of $7.2 million in the same period in 2025. The prior year's income was significantly boosted by a one-time $27.1 million gain from the change in fair value of warrant liability, which expired in June 2025.
• Rising R&D Spend: Research and development expenses increased by $11.8 million (77%) year-over-year for the six-month period, driven primarily by the advancement of the Phase 3 PTCL trial and Phase 2 atopic dermatitis trial for soquelitinib.
• Capital Raise: In January 2026, the company completed a follow-on public offering, raising approximately $189.4 million in net proceeds. This significantly bolstered liquidity compared to the prior year.
• Investment in Angel Pharmaceuticals: The company invested an additional $5.0 million in its China-based partner, Angel Pharmaceuticals, during the period, increasing its ownership interest to approximately 49%.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities ($215.2 million) are sufficient to fund operations into the second quarter of 2028.
• Clinical Milestones:
  • Soquelitinib (PTCL): The Phase 3 trial is ongoing. An interim futility analysis is anticipated in early 2027.
  • Soquelitinib (Atopic Dermatitis): Positive Phase 1 results were announced in January 2026. A Phase 2 trial initiated in March 2026 is expected to enroll ~200 patients.
  • Angel Pharmaceuticals: Partner is conducting Phase 1b/2 trials in China; results from Cohort 1 are expected late in 2026.
• Regulatory Status Change: As of June 30, 2026, the company will no longer qualify as a "smaller reporting company" beginning January 1, 2027, leading to increased disclosure and compliance requirements.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital to fund commercialization, reliance on third-party manufacturers, and potential regulatory delays. The company has no approved products and has never generated revenue.

Investor Verification Checklist

• Verify the enrollment rates and interim data timelines for the Phase 3 soquelitinib trial in PTCL.
• Confirm the burn rate and cash runway projections given the increased R&D spend in 2026.
• Review the terms and progress of the Angel Pharmaceuticals partnership, specifically regarding the $5.0 million investment and equity ownership.
• Monitor the transition from "smaller reporting company" status and its impact on future reporting costs and internal controls (Section 404).
• Assess the potential impact of the Inflation Reduction Act and new tariff policies on future pricing and commercialization strategies.